Age-associated serum and plasma proteins and lipids in about 3,800 older Japanese adults
In about 3,800 Japanese adults aged 40 and older, several proteins and lipids were associated with age across five cohorts; the abstract reports reproducibility across serum and plasma and in independent cohorts. [1]
Automatic summary · not editorially reviewed
The key findings
The study analyzed serum and plasma from about 3,800 Japanese adults aged 40 and older, focusing on people with comorbidities. [1]
CXCL9, CCL11, PC 31:0 and PC 32:0 were positively associated with age across five cohorts, while LPC-LA and LPC-AA were negatively associated. [1]
The abstract reports cross-platform consistency between Olink Target 96 and Target 48, with direct validation in Cohort 2. [1]
The source at a glance
- Study type / format
- Abstract of a multi-cohort biomarker study
- Population / context
- About 3,800 Japanese adults aged 40 and older, in a comorbidity-enriched population.
- Summary based on
- Study abstract
- Original publication
- August 1, 2026
Age associations in five Japanese cohorts
The study analyzed serum and plasma from about 3,800 Japanese people aged 40 and older, with a focus on people with comorbidities. It looked for proteins and lipids associated with age and checked how reproducible and robust these links were. The abstract describes this as the largest study of its kind in a comorbidity-enriched Japanese population.
Supporting source [1]
Chemokines up, lysophosphatidylcholines down with age
Across five cohorts, the chemokines CXCL9 and CCL11 and the phosphatidylcholines PC 31:0 and PC 32:0 were positively associated with age. The lysophosphatidylcholines LPC-LA and LPC-AA showed negative associations with age. These are associations, not evidence that these molecules cause aging. The abstract reports that the relationships were reproduced across serum and plasma and replicated in independent cohorts.
Supporting source [1]
Cross-platform checks and stated scope
The abstract reports consistency between two measurement platforms, Olink Target 96 with relative values and Target 48 with absolute quantification, plus direct validation in Cohort 2. The authors describe the main contribution as technical: a set of robust biomarkers of aging across platforms and sample types. They present these as a reference for research such as risk stratification and biological age assessment, not as a clinical test or treatment.
Supporting source [1]
How to interpret this
This is based on the abstract only; the full text was not reviewed. The abstract gives no effect sizes, no details on how age was measured, and no information on how comorbidities were defined or on potential confounders. Associations do not show causation, and the proposed uses in risk stratification and biological age assessment are research directions, not validated clinical applications.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Tokuoka SM, Hamano F, Kobayashi A, Natsume T, Sugiyama M, Matsuda K, Oda Y. · europepmc.org · August 1, 2026